Navigation Links
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Date:10/12/2008

Quark siRNAs Examined Alone and in Combination with Chemotherapy

FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008. The paper, entitled "RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy," reports on research performed in collaboration with Professor Shyam Biswal of the Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University. The results provide a basis for a potential new drug candidate to be added to Quark's pipeline.

The study examined efficacy of RNAi-mediated reduction of Nuclear Factor Erythroid-2-Related Factor 2 (Nrf2) expression in vitro and in in vivo mouse NSCLC xenograft models alone or in combination with chemotherapy. The results show that RNAi-mediated reduction of Nrf2 expression generates reactive oxygen species, suppresses tumor growth, and increases sensitivity to chemotherapeutic drug-induced cell death.

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer of Quark Pharmaceuticals, said, "Nrf2 appears in our IP portfolio as a novel drug target for cancer treatment. Discovery of the target's role in cancer was made years ago, using our proprietary functional high throughput drug target discovery method, BiFAR(TM), when we looked for genes whose inhibition could sensitize cancer cells to apoptosis. Since then, much progress has been made to study the concept of Nrf2 inhibition for cancer treatment by the scientific community. One of the major contributors in this field is Prof. Biswal from Johns Hopkins University with whom we have established a very productive collaboration. The results of the present study reconfirm our interest in the target and provide for new product opportunities within our expanding siRNA product pipeline. Quark has the deepest clinical-stage pipeline of siRNAs under development, with efficacy studies completed for several compounds, many stemming from our internal gene discovery programs, and ongoing research efforts to further broaden our range of siRNA product candidates."

Professor Shyam Biswal of the Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University, principal investigator of the study said, "RNAi-mediated reduction of Nrf2 expression represents a potential breakthrough for treating non-small cell lung cancer. Suppression of Nrf2 effectively inhibited tumor growth and increased sensitivity to chemotherapeutic drug-induced cell death in the study. It is critical that we establish new and effective therapies for NSCLC, which is intrinsically resistant and generally nonresponsive to initial chemotherapy, and commonly leads to acquired resistance even as therapies become increasingly sophisticated. We are encouraged by Quark's continued evaluation and development of therapeutics that target Nrf2 to inhibit tumor growth and circumvent chemoresistance."

Quark Pharmaceuticals has recently announced QPI-1007, its first drug candidate to utilize a novel siRNA structure developed by Quark with freedom to operate in the siRNA intellectual property space. QPI-1007 is currently being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases.

The publication can be seen online at http://cancerres.aacrjournals.org/cgi/content/abstract/68/19/7975.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery and DGFi, about to start phase I/II for prevention of delayed graft function in kidney transplantation. Based on publicly available information, Quark believes AKIi-5 was the first siRNA administered systemically in a human clinical study.

In addition, Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally. The Company expects to utilize the structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com

Quark Pharmaceuticals, Inc.

Juliana Friedman

+972 89 30 5111

jfriedman@quarkpharma.com

The Ruth Group (investors / media)

Sara Ephraim / Janine McCargo

(646) 536-7004 / 7033

sephraim@theruthgroup.com

jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... HEIGHTS, Utah , Feb. 8, 2016 /PRNewswire/ ... and distributor of advanced-technology medical devices and rehabilitation ... related markets, congratulates the Denver Broncos, football team ... Kelvyn H. Cullimore Jr. , Chairman and Chief ... of excellence and we look forward to enhancing ...
(Date:2/8/2016)... 2016 --> ... Allied Market Research titled, "World Synthetic Biology ... estimates the world synthetic biology market to be ... technology segment would continue to lead the market ... collectively, held around half of the market share ...
(Date:2/5/2016)... OAKS, Calif. , Feb. 5, 2016 Amgen ... 5 th Annual Global Healthcare Conference at 9:15 a.m. ... York City . David W. Meline , executive ... at the conference. Live audio of the presentation can be ... , under Investors. A replay of the webcast will also ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its affiliated ... , Gary D. Radine, who recently retired as president and CEO of Delta Dental ... 2015 CEO of the Year , helped lead the effort to raise funds for ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... of organizations. DocuSyst provides a cloud hosted environment for FileHold software that ... integration with various 3rd party applications using the FileHold web services API. DocuSyst ...
(Date:2/8/2016)... ... 08, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to a ... derived from a cluster of melanin when exposed to sunlight. Although most moles are ... lifetime of embarrassment. Historically, mole removal has involved a painful, often expensive ...
(Date:2/8/2016)... ... , ... According to research by the National Association of ... be certified or obtain continuing education. To increase patient awareness of the lack ... campaign to inform dentists and patients about the possible lack of skills and ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... Facial Plastics, has added Kybella® to his medical and surgical expertise. Technically known ... approved FDA injectable medication used as a non-surgical alternative for reduction of fat ...
Breaking Medicine News(10 mins):